<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">697774</article-id><article-id pub-id-type="doi">10.17816/dv697774</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DERMATOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">PHENOTYPE-BASED APPROACH IN THE TREATMENT OF ROSACEA: RELEVANCE AND PRACTICAL APPLICATION</article-title><trans-title-group xml:lang="ru"><trans-title>ФЕНОТИПИЧЕСКИЙ ПОДХОД В ТЕРАПИИ РОЗАЦЕА: АКТУАЛЬНОСТЬ И ПРАКТИЧЕСКОЕ ПРИМЕНЕНИЕ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3933-6922</contrib-id><contrib-id contrib-id-type="spin">6254-9643</contrib-id><name-alternatives><name xml:lang="en"><surname>vashkevich</surname><given-names>arina</given-names></name><name xml:lang="ru"><surname>Вашкевич</surname><given-names>Арина Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Dermatovenereology</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, доцент, доцент кафедры дерматовенерологии</p></bio><email>aavashk@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">North-Western State Medical University named after I.I. Mechnikov</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО СЗГМУ им. И.И. Мечникова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-02-04" publication-format="electronic"><day>04</day><month>02</month><year>2026</year></pub-date><volume>29</volume><issue>1</issue><issue-title xml:lang="ru"/><history><date date-type="received" iso-8601-date="2025-12-04"><day>04</day><month>12</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-12-17"><day>17</day><month>12</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; , Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; , Эко-Вектор</copyright-statement><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-02-04"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/697774">https://rjsvd.com/1560-9588/article/view/697774</self-uri><abstract xml:lang="en"><p>Rosacea is a chronic inflammatory skin disorder with a multifactorial pathogenesis and a significant impact on patients’ quality of life. Despite its superficial resemblance to acne, rosacea is characterized by distinct pathophysiological mechanisms, including neurovascular dysregulation, alterations in innate immunity, TRP-channel hyperreactivity, dysregulation of the cathelicidin pathway, and involvement of microorganisms such as Demodex folliculorum. Disease manifestations are strongly influenced by external triggers, including ultraviolet radiation, temperature fluctuations, alcohol intake, spicy foods, and psychological stress. Recent advances have shifted the focus from subtype-based classification toward the phenotype-driven approach proposed by the ROSCO consensus group. This strategy enables individualized assessment of clinical signs and facilitates the selection of personalized therapy aimed at achieving “clear” or “almost clear” skin. Key management components include skincare optimization, trigger avoidance, lifestyle modification, and appropriate use of topical and systemic treatments. Among topical therapies, 1% ivermectin has gained relevance due to its dual anti-inflammatory and anti-Demodex effects. Clinical trials have demonstrated its superiority over metronidazole in reducing inflammatory lesions, prolonging remission, and improving overall treatment outcomes. Overall, contemporary management of rosacea relies on comprehensive targeting of pathogenic mechanisms, careful consideration of clinical phenotypes, and pursuit of durable disease control with meaningful improvement in patients’ quality of life.</p></abstract><trans-abstract xml:lang="ru"><p>Розацеа представляет собой хроническое воспалительное заболевание кожи с многофакторным патогенезом и выраженным влиянием на качество жизни пациентов. Несмотря на внешнюю схожесть с акне, розацеа характеризуется иной патофизиологией, включающей нейроваскулярную дисрегуляцию, нарушения врождённого иммунитета, гиперреактивность TRP-каналов, дисбаланс кателицидинового пути и роль микроорганизмов, включая <italic>Demodex</italic><italic> </italic><italic>folliculorum</italic><italic>.</italic> Существенное влияние на течение заболевания оказывают внешние триггеры: ультрафиолетовое излучение, температурные воздействия, алкоголь, острая пища и стрессовые факторы.</p> <p>Современные представления о розацеа сместили акцент от классификации по подтипам к фенотипически ориентированному подходу, рекомендованному консенсусом ROSCO. Такой подход позволяет учитывать индивидуальные клинические признаки и подбирать персонализированную терапию, направленную на достижение состояния «чистой» кожи. Значительное внимание уделяется уходу за кожей, модификации образа жизни и исключению индивидуальных триггеров.</p> <p>В терапии папуло-пустулёзной розацеа важная роль отводится топическим препаратам, среди которых ивермектин 1% занимает особое место благодаря сочетанию противовоспалительного эффекта и воздействия на популяцию <italic>Demodex</italic>. Клинические исследования демонстрируют его высокую эффективность в снижении числа воспалительных элементов, достижении стойкой ремиссии и превосходстве над метронидазолом.</p> <p>Таким образом, современные подходы к ведению розацеа предполагают комплексное воздействие на патогенетические механизмы заболевания, учёт индивидуальных фенотипических особенностей и стремление к достижению контролируемого, длительного терапевтического результата.</p></trans-abstract><kwd-group xml:lang="en"><kwd>rosacea, pathogenesis, phenotypic approach, ivermectin, Demodex, review</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>розацеа, патогенез, фенотипический подход, ивермектин, Demodex, обзор</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Клинические рекомендации. Розацеа / Российское общество дерматовенерологов и косметологов. — 2020. — URL: https://www.rodv.ru/klinicheskie-rekomendacii/ (дата обращения: 15.11.2025).</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Потекаев Н.Н., Хамаганова И.В., Новожилова О.Л., Лебедева Г.А. Эпидемиология розацеа // Клиническая дерматология и венерология. — 2016. — Т. 15, № 1. — С. 4–7. — DOI: 10.17116/klinderma20161514-7.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Saurat J.H., Halioua B., Baissac C., et al. Epidemiology of acne and rosacea: a worldwide global study // J Am Acad Dermatol. — 2024. — 90(5):1016–1018. — DOI: 10.1016/j.jaad.2023.12.038.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Chen C., Wang P., Zhang L., et al. Exploring the pathogenesis and mechanism-targeted treatments of rosacea: previous understanding and updates // Biomedicines. — 2023. — 11(8):2153.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Geng R.S.Q., Bourkas A.N., Sibbald R.G., Sibbald C. Biomarkers in rosacea: a systematic review // J Eur Acad Dermatol Venereol. — 2024. — 38(6):1048–1059.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kosciuczuk E.M., Lisowski P., Jarczak J., et al. Cathelicidins: family of antimicrobial peptides. A review // Mol Biol Rep. — 2012. — 39(12):10957–10970.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Alalwani S.M., Sierigk J., Herr C., et al. The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils // Eur J Immunol. — 2010. — 40(4):1118–1126.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>van Zuuren E.J., Fedorowicz Z., Carter B. Interventions for rosacea // Cochrane Database Syst Rev. — 2021. — 5:CD003262.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Steinhoff M., Schauber J., Leyden J.J. New insights into rosacea pathophysiology: a review of recent findings // J Am Acad Dermatol. — 2013. — 69(6 Suppl 1):S15–S26.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Li J., Gower A.C., Hasan T., et al. Heritability of rosacea: a twin study // J Invest Dermatol. — 2015. — 135(5):1324–1327.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Forton F., De Maertelaer V. Rosacea and Demodex mites: the firm relationship // J Eur Acad Dermatol Venereol. — 2017. — 31(5):787–792.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Koller S., Kownatzki E., Reinhold D. Chitin stimulates inflammatory cytokine production in human peripheral blood mononuclear cells // Exp Dermatol. — 2019. — 28(3):348–351.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Lacey N., Delaney S., Kavanagh K., Powell F.C. Mite-related bacterial antigens stimulate inflammatory cells in rosacea // Br J Dermatol. — 2007. — 157(3):474–481.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Liu J., Sheha H., Tseng S.C. Pathogenic role of Demodex mites in blepharitis // Curr Opin Allergy Clin Immunol. — 2020. — 20(5):451–456.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Yamasaki K., Gallo R.L. The molecular pathology of rosacea // J Dermatol Sci. — 2009. — 55(2):77–81.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Culp B., Scheinfeld N. Rosacea: a review // P T. — 2009. — 34(1):38–45. PMID: 19562004; PMCID: PMC2700634.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Drake L., ред. National Rosacea Society. New survey pinpoints leading factors that trigger symptoms // Rosacea Review. — 2002, Summer. — URL: http://www.rosacea.org/rosacea-review/2002/summer/new-survey-pinpoints-leading-factors-that-trigger-symptoms (дата обращения: 17.05.2020).</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wilkin J., Dahl M., Detmar M., et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea // J Am Acad Dermatol. — 2002. — 46(4):584–587. — DOI: 10.1067/mjd.2002.120285.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Tan J., Almeida L.M., Bewley A., et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSCO panel // Br J Dermatol. — 2017. — 176(2):431–438. — DOI: 10.1111/bjd.15122.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Schaller M., Almeida L.M., Bewley M., et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSCO 2019 panel // Br J Dermatol. — 2020. — 182(5):1269–1276. — DOI: 10.1111/bjd.18420.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Schaller M., Almeida L.M., Bewley A., et al. Rosacea treatment update: recommendations from the global ROSCO panel // Br J Dermatol. — 2017. — 176(2):465–471. — DOI: 10.1111/bjd.15173. PMID: 27861741.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Clanner-Engelshofen B.M., Bernhard D., Dargatz S., et al. S2k guideline: Rosacea // JDDG. — 2022. — 20:1147–1165. — DOI: 10.1111/ddg.14849.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Leyer A., Rieg G., Müller M., et al. Ivermectin zur Behandlung der Skabies norwegica bei AIDS Patienten. Ein neues Therapiekonzept – dargestellt an 2 Fallbeispielen // AIDS-Forschung (AIFO). — 1994. — 9:608.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Yang F., Wang L., Song D., et al. Signaling pathways and targeted therapy for rosacea // Front Immunol. — 2024. — 15:1367994.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>de Menonville S.T., Rosignoli C., Soares E., et al. Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models // Dermatol Ther (Heidelb). — 2017. — 7(2):213–225. — DOI: 10.1007/s13555-017-0176-3.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Butcher A.M., Cheng J., Shafiq F., et al. Topical ivermectin modulates the skin microbiome and improves symptoms of rosacea // J Invest Dermatol. — 2022. — 142(8 Suppl):S144.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Olah P., Reuvers N., Radai Z., et al. Microbe-host interaction in rosacea and its modulation through topical ivermectin // J Invest Dermatol. — 2025. — 145(10):2576–2587.e8. — DOI: 10.1016/j.jid.2025.03.031.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Nakatsuji T., Cheng J.Y., Butcher A., et al. Topical ivermectin treatment of rosacea changes the bacterial microbiome of the skin // J Invest Dermatol. — 2024. — DOI: 10.1016/j.jid.2024.10.029.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Одобренные ОХЛП/ЛВ препарата Солантра®, крем для наружного применения (ивермектин) 1 %, Рег. уд. ЛП-№(009844)-(РГ-RU). — URL: https://lk.regmed.ru/Register/EAEU_SmPC.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Stein L., Kircik L., Fowler J., et al. Efficacy and safety of ivermectin 1 % cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies // J Drugs Dermatol. — 2014. — 13:316–323.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Taieb A., Ortonne J.P., Ruzicka T., et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial // Br J Dermatol. — 2015. — 172(4):1103–1110. — DOI: 10.1111/bjd.13408.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Taieb A., Khemis A., Ruzicka T., et al. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study // J Eur Acad Dermatol Venereol. — 2016. — 30(5):829–836. — DOI: 10.1111/jdv.13537.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Одобренная инструкция по применению лекарственного препарата Мирвазо® Дерм, гель для наружного применения (бримонидин) 0,5 %. Рег. уд. № ЛП – 003563. — URL: https://grls.minzdrav.gov.ru/</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Dall'Oglio F., Nasca M.R., Vitale P., et al. Inflamed rhinophyma treated with topical ivermectin: a randomized controlled study // J Am Acad Dermatol. — 2024. — 91(3):519–521.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Государственный реестр лекарственных средств РФ (ГРЛС). — URL: https://grls.rosminzdrav.ru</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Schaller M., Schöfer H., Homey B., et al. Rosacea management: update on general measures and topical treatment options // J Dtsch Dermatol Ges. — 2016. — 14(suppl 6):17–27.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>van Zuuren E.J., Fedorowicz Z., Carter B., et al. Interventions for rosacea // Cochrane Database Syst Rev. — 2015. — 4:CD003262.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Gold L.S., Papp K., Lynde C., et al. Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study // J Drugs Dermatol. — 2017. — 16:909–916.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Johnson S.M., Berg A., Barr C. Managing rosacea in the clinic: from pathophysiology to treatment—a review of the literature // J Clin Aesthet Dermatol. — 2020. — 13(4 Suppl): S17–S22. — PMID: 32802248; PMCID: PMC7384638.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Tan J., Berg M., Gallo R.L., et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSCO panel // Br J Dermatol. — 2017. — 176(2):431–438.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Schaller M., Steinhoff M., Araviiskaia E., et al. Rosacea treatment update: recommendations from the global ROSCO panel // Br J Dermatol. — 2017. — 176(2):465–471.</mixed-citation></ref></ref-list></back></article>
